| Autor: |
Wardle, Melissa T., Allen, Samantha E., Gamboa, Ricardo, Vilchez, Percy, O'Neal, Seth E., Muro, Claudio, Lescano, Andrés G., Moyano, Luz M., Gonzalvez, Guillermo E., González, Armando E., Gilman, Robert H., García, Héctor H., Verastegui, Manuela R., Bustos, Javier A., Zimic, Mirko, Gonzales, Isidro, Saavedra, Herbert, Sanchez, Sofia S., Martinez, Manuel, Castillo, Yesenia, Toribio, Luz, Arroyo, Gianfranco, Orrego, Miguel A., Chile, Nancy, Mayta, Holger, Pajuelo, Monica, Santivañez, Saul, Gonzalez-Gustavson, Eloy, Gomez-Puerta, Luis, Gavidia, Cesar M., Vargas-Calla, Ana, Lopez, Maria T., Nash, Theodore E., Handali, Sukwan, Noh, John, Friedland, Jon |
| Zdroj: |
The Lancet Regional Health - Americas; October 2024, Vol. 38 Issue: 1 |
| Abstrakt: |
Mass drug administration (MDA) with niclosamide (NSM) can be used to control taeniasis, the cause of neurocysticercosis. NSM is 84.3% effective against taeniasis and is considered safe as it is not absorbed from the intestinal tract. However, information on its safety and effectiveness during MDA is limited. We evaluated the effectiveness of NSM and reported adverse events (AEs) during a cysticercosis elimination program in Tumbes, Peru. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
